Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

Allergy Therapeutics hosts satellite symposium at EAACI 2017

~ World-leading experts discuss allergy immunotherapies ~

Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces today that a satellite symposium entitled: "The Best Therapies by Design"  was held at the 36^th Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Helsinki, Finland on 18 June 2017, providing an overview of the technologies and strategies involved in designing the best immunotherapies.

Chaired by Professor Stephen Durham, four world-leading experts in the field of allergy, pollen, and immunotherapy vaccine delivery, Jörg Kleine-Tebbe, Erika Jensen-Jarolim, Uwe Berger & Tim Higenbottam presented on the strategy, design and considerations involved in creating immunotherapies such as Allergy Therapeutics' flagship product, Pollinex Quattro®.  Uwe Berger and Erika Jensen-Jarolim discussed the importance of highlighting relevant allergens and characterising them sufficiently.  Jörg Kleine-Tebbe discussed why successful immunotherapy requires identification of the optimal dose before Phase III studies are begun, before Tim Higenbottam finished the session describing the results recently gained from the Group's clinical studies.

Manuel Llobet, Chief Executive Officer, commented: "We are delighted with our progress in developing the next generation of allergen immunotherapy products. Our latest clinical data on dose-ranging confirms that our unique allergen-specific immunotherapies are formulated to the optimal strength and we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free products."

Satellite Symposium: "The Best Therapies by Design"

1.   The importance of defining the optimal dose - Jörg Kleine-Tebbe, Allergie und Asthma - Zentrum Westend, Berlin.

2.   Molecular fingerprinting of complex allergoids - Erika Jensen-Jarolim, Institute of Pathophysiology and Allergy Research, Medical University Vienna.

3.   Rationale for broad spectrum grass immunotherapy - Uwe Berger, Medical University of Vienna. Head of Aerobiology & Pollen Information Research Unit.

4.   Defining the plateau of the efficacy for Allergen Specific Immunotherapy - Tim Higenbottam, R&D Director, Allergy Therapeutics.

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / Ivar Milligan

allergytherapeutics@consilium-comms.com 

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.  The Group sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities.  The Group employs c.495 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

About the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI)

The EAACI Congress 2017 is a congress organised by the European Academy of Allergy and Clinical Immunology (EAACI) which offers a unique opportunity to learn about new discoveries and exchange experience with professionals in the field of allergy and clinical immunology. The Congress is taking place in Helsinki, Finland from 17-21 June 2017.